ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KARD / news
DMRA (35) OMER (41) MLYS (33) OPK (40) ⌘ Pro Terminal →

Why KARD Stock advanced +0.57% Today — RQD Quant Desk Flash

$14.21 +0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.20

Kardigan Inc. (KARD) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KARD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kardigan Inc. (NASDAQ: KARD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $14.21 (+0.57% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KARD ranks #327 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KARD compare to DMRA and OMER in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KARD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DMRA (Damora Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and OMER (Omeros Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.29B). Among the 5-stock peer group, KARD leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KARD?
▼

Per KARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002123613), Kardigan Inc. generated $164.2M in revenue, $0 in net income, and $0 in free cash flow against $390.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.20 (-0.09%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 22.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (10)Whales (5)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$28 Bull$13 Base$10 Bear
📬 FREE KARD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KARD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY KARD SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 22.7% FCF Margin ($37.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$13.52-5% Next Q
Q2 (-2Q)
41
Grade D$12.85+6.8% Next Q
Q3 (-1Q)
43
Grade D$13.73+3.5% Next Q
Current
46
Grade D$14.21-6.1% Hist 90D α
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KARD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KARD currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.94) and Max Pain ($14.92) forces dealer call-delta covering toward $28.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KARD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KARD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why KARD Stock advanced +0.57% Today — RQD Quant Desk Flash

Kardigan Inc. (KARD) advanced +0.57% to $14.21, trading at 13% of its 52-week range ($12.23 – $27). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 13% of its 52-week range ($12.23 – $27) with RSI-14 at 48.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $14.21 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $37.2M annual free cash flow.
Live KARD Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KARD)

  • ✓Walkthrough of KARD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KARD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.41%⚡ TESTING RESISTANCE
2026-11-04O $14.13H $14.21L $14.13C $14.21VOL 462.3K
RES: $14.18SUP: $9.23SMA50: $15.94SMA200: $18.83
$28.03$23.75$19.47$15.18$10.90RES $14.18SUP $9.23$14.212026-06-182026-07-242026-08-272026-10-012026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KARD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KARD Butterfly Map → + Track KARD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KARD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KARD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KARD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KARD)

Health Care Rank #327 of 1015 ⚔️ DMRA vs KARD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KARD vs. DMRA, OMER, MLYS, OPK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kardigan Inc. (KARD) ranks #327 by composite RQD confidence (46/100, grade D) and #317 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, KARD leads on earnings valuation at N/A trailing P/E, while OPK leads on capital efficiency and profitability with -10.2% ROIC and 33.9% gross margin. KARD currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KARD ACTIVE
Kardigan Inc.
D 46/100 — — — +0.57% $1.33B Benchmark Subject
DMRA
Damora Therapeutics Inc.
D- 35/100 — — -35.0% +0.51% $1.33B /dmra-vs-kard →
OMER
Omeros Corporation
D- 41/100 — — -35.0% -3.31% $1.29B /omer-vs-kard →
MLYS
Mineralys Therapeutics Inc.
E 33/100 — — -28.4% -14.47% $1.37B /mlys-vs-kard →
OPK
OPKO Health Inc.
D- 40/100 — 33.9% -10.2% +3.61% $1.28B /opk-vs-kard →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002123613 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kardigan Inc. (KARD) reported GAAP revenue of $164.2M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KARD closed FY2025 with $390.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $164.2M $0 — — $390.9M —

3. KARD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kardigan Inc. (NASDAQ: KARD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $14.21 (+0.57% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KARD ranks #327 in composite RQD confidence.

How does KARD compare to DMRA and OMER in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KARD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DMRA (Damora Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and OMER (Omeros Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.29B). Among the 5-stock peer group, KARD leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KARD?

Per KARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002123613), Kardigan Inc. generated $164.2M in revenue, $0 in net income, and $0 in free cash flow against $390.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KARD trading relative to its 50-day, 200-day, and 52-week technical levels?

KARD last traded at $14.21 (+0.57% on volume of 462,309 shares), positioning the stock -10.85% below its 50-day simple moving average ($15.94) and -24.54% below its 200-day simple moving average ($18.83). Across its 52-week range of $12.23 to $27.00, KARD sits at the 13.4% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.43 to $15.99).

Direct Sub-Reports: KARD RQD Cockpit KARD 12M Forecast KARD Earnings & Move KARD Dividends & DRIP KARD Insiders & 13F KARD Whale Options KARD Profit Sankey KARD News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

KARD — Kardigan Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kardigan Inc. (KARD) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $14.21 (+0.57% 1D, market capitalization $1.33B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kardigan Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $1.3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kardigan Inc. (KARD) reported $164.2M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $390.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $12.23 – $27.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. A prospective investor should note that the absence of mapped links means ripple effects cannot be assessed from the supplied data.

  • Key Question #1: Can KARD sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $164.2M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KARD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KARD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kardigan Inc. (KARD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KARD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KARD Bull vs. Bear Conversation Board — What's Your Call at $14.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KARD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KARD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $16.96 (+20.0%)
📌 Pinned Debate

Positive analyst initiations from UBS (buy) and Baird (Outperform, $43 target) with a 13/20 forensic balance-sheet score.

Long KARD at $14.13 targeting $16.96. Positive analyst initiations from UBS (buy) and Baird (Outperform, $43 target) with a 13/20 forensic balance-sheet score.. Institutional whale score is 5/20 and the risk/reward vs. the $12.23 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — KARD's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $11.45 (-19.0%)
Spot @ $14.13

ROIC and FCF yield both at 0% with a 45/100 RQD score, rated Underperform / Distribution Warning.

I respect the product at Kardigan Inc., but the stock at $14.13 is a different story. ROIC and FCF yield both at 0% with a 45/100 RQD score, rated Underperform / Distribution Warning.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE